Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer

Conditions:   Human Papilloma Virus Infection;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Tongue CancerInterventions:   Drug: veliparib;   Other: placebo;   Drug: cisplatin;   Drug: fluorouracil;   Radiation: radiation therapy;   Drug: hydroxyurea;   Drug: paclitaxel;   Drug: carboplatinSponsor:   National Cancer Institute (NCI)Recruiting - verified August 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials